XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity.

J Antimicrob Chemother

Antimicrobial Research Centre and Institute of Molecular and Cellular Biology, University of Leeds, Leeds, UK.

Published: October 2009

Objectives: XF-73 is a novel porphyrin antibacterial agent previously reported to inhibit a range of gram-positive bacterial species, including Staphylococcus aureus. Its mode of action is unknown. Using S. aureus as a model organism we sought to examine the basis of its antibacterial activity.

Methods: The effects of XF-73 on the growth and survival of S. aureus SH1000 were investigated by viable count and culture absorbance techniques. Inhibition of macromolecular synthesis and disruption of membrane integrity after exposure to XF-73 were examined by radiolabelling experiments, the BacLight fluorescent dye assay and measurement of K(+) and ATP leakage from the cell. The effect of XF-73 on a staphylococcal coupled transcription-translation system was also investigated.

Results: XF-73 was rapidly bactericidal against S. aureus SH1000 and demonstrated more rapid killing kinetics than all other comparator agents when tested at an equivalent multiple (4x) of the MIC. Exposure of S. aureus to XF-73 for 10 min completely inhibited DNA, RNA and protein synthesis. XF-73 had no effect on transcription and translation in vitro. Cells exposed to XF-73 gave a positive response in the BacLight assay, which detects membrane damage. The drug also caused substantial loss of K(+) and ATP from the cell, but did not promote bacterial lysis.

Conclusions: XF-73 exhibited rapid membrane-perturbing activity, which is likely to be responsible for inhibition of macromolecular synthesis and the death of staphylococci exposed to the drug.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkp299DOI Listing

Publication Analysis

Top Keywords

xf-73
10
xf-73 novel
8
aureus sh1000
8
inhibition macromolecular
8
macromolecular synthesis
8
aureus
5
novel antistaphylococcal
4
antistaphylococcal membrane-active
4
membrane-active agent
4
agent rapid
4

Similar Publications

Article Synopsis
  • Nasal carriers were split into two groups to receive either XF-73 nasal gel or a placebo, administered five times over approximately 24 hours before cardiac surgery.
  • Patients using XF-73 showed a significant reduction in bacteria levels after two doses, with a decrease of -2.2 log CFU/mL, while the placebo group had almost no reduction at -0.01 log CFU/mL.
  • Post-surgery, 46.5% of the XF-73 group required anti-staphylococcal antibiotics compared to 70% in the placebo group, indicating a significant reduction in post-operative antibiotic usage for those treated with XF-73 (p = 0.045).
View Article and Find Full Text PDF

XF-73 (exeporfinium chloride) is a synthetic, di-cationic porphyrin derivative with rapid, potent bactericidal properties and a low propensity for engendering bacterial resistance. It is being developed clinically for the decolonization of in the nasal cavity to prevent post-operative staphylococcal infections. This study reports the minimum inhibitory concentration (MIC) of XF-73 in comparison to 22 antibiotics against a panel of >2,500 clinical isolates composed of 16 different Coagulase-positive and -negative species from 33 countries.

View Article and Find Full Text PDF

Compared with antibiotics for treating bacterial infections, there are a limited number of antifungal agents. This is due to several factors, including the difficulties of identifying suitable antifungals that target the fungal cell without damaging host cells, and the reduced rates of diagnosis of fungal infections compared with those caused by bacteria. The problem of treating fungal infections is exacerbated by an increasing incidence of antifungal resistance among human fungal pathogens.

View Article and Find Full Text PDF

Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF-73), Against Antibiotic-Resistant Bacteria in Mouse Superficial Skin Infection Models.

Infect Drug Resist

July 2023

Department of Immunology, Key Laboratory of Immune Microenvironment and Disease of the Educational Ministry of China, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, People's Republic of China.

Background: The number of incidences of antimicrobial resistance is rising continually, necessitating new and effective antibacterial drugs. The present study aimed to assess the in vitro and in vivo activity of XF-73 against antibiotic-resistant () isolates and to investigate the potential mechanism of action of XF-73.

Methods: The in vitro antibacterial activity of XF-73 and comparator antibacterial drugs, (mupirocin, fusidine, retapamulin, vancomycin, erythromycin, linezolid and daptomycin), against (both antibiotic sensitive and resistant strains) was assessed using a broth microdilution method.

View Article and Find Full Text PDF

We studied 83 cardiac-surgery patients with nasal carriage who received 4 intranasal administrations of XF-73 nasal gel or placebo <24 hours before surgery. One hour before surgery, patients exhibited a nasal carriage reduction of 2.5 log with XF-73 compared to 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!